Global Immunosuppressant Drugs Market - Forecasts from 2022 to 2027

The Global Immunosuppressant Drugs Market was valued at US$21.586 billion in 2020 and it is predicted to grow at a CAGR of 13.44% and will reach at US$51.175 billion in 2027.

The increasing number of organ transplants worldwide is one of the major drivers of the global immunosuppressant drug market. There has been a rising demand for transplants for various organs, such as the liver, pancreas, kidney, and lungs. According to the latest Global Observatory on Donation and Transplantation statistics, 146,840 organs were transplanted annually in 2018, representing a rise of 5.6 percent from the previous year. Also, according to the findings of the World Health Organization (WHO), around 91,800 kidney transplant procedures, 30,800 liver transplants, and 6,200 lung transplants took place globally during the same year. Other factors that have led to a worldwide increase in demand for organ transplantation are the rising incomes, the spread of personal health insurance, better and advanced healthcare facilities, and an ageing population. According to World Population Prospects: the 2019 Revision, the aged population (65 years and above) outnumbered the children population (under five years of age) globally for the first time in 2018. Also, the number of people aged 80 years and above is projected to triple by 2050 from 2018 figures. Governments and global organizations are creating more awareness about organ donation to reduce the organ shortage. As such, the rising number of organ donors will continue to drive up the number of organ transplant procedures, which will significantly propel the growth of the global immunosuppressant drugs market during the next five years. Furthermore, advancements in organ transplantation procedures will further encourage people to sign up for the procedure, thus positively impacting the global immunosuppressant drug market growth.

The introduction of the generic version of immunosuppressant drugs has further boosted the market growth. These standard versions have substantially reduced the overall cost of the transplant procedure. Since individuals who receive organ transplants must take life-long immunosuppressive drugs to prevent rejection, the launch of various common versions is bolstering the overall market growth. Lupin has recently launched generic immunosuppressant Tacrolimus capsules in the U.S. market after its alliance partner Concord Biotech Ltd received approval for ANDA, its new drug application, from the U.S. Food and Drug Administration (USFDA).

Another major factor fueling the market growth of the immunosuppressant drugs market globally is the growing prevalence of autoimmune diseases across the globe. According to the American Autoimmune Related Diseases Association (AARDA), it can take an average of five years and five doctors to get diagnosed with an autoimmune disorder. However, autoimmunity has become one of the most common disease categories.

Key market players adopt various growth strategies to capture a larger share in the global immunosuppressant drugs market and maintain their position. For example, GlaxoSmithKline PLC announced the approval of its newly developed intravenous (IV) formulation of Benlysta by the USFDA. High R&D investments in developing advanced immunosuppressant drugs by global vendors will also contribute to the global market growth during the forecast period. For instance, Pfizer is developing a new immunosuppressive drug based on inhibiting JAK3, a critical enzyme in the immune system, to prevent transplant rejection. In December 2018, Veloxis Pharmaceuticals announced that the company had received approval from the USFDA for a new indication for Envarsus XR (tacrolimus extended-release tablets) to prevent organ rejection in kidney transplant patients in combination with other immunosuppressants.

The global immunosuppressant drugs market is segmented on drug class, application, distribution channel, and geography. By drug class, the global immunosuppressant drugs market has been classified as calcineurin inhibitors, mTOR inhibitors, antibodies, and others. Based on application, Market Segmentation: has been done for organ transplantation and autoimmune disorder. The global immunosuppressant drugs market has been segmented online and offline by distribution channels.

COVID-19 Impact

The disease's outbreak inflated the market for immunosuppressant drugs, as the disease claimed the lives of millions of people worldwide. Tocilizumab and other Calcineurin Inhibitors played a significant role in saving people's lives by reducing the impact of the disease. However, the high cost and limited supply of the drug made for revenue as people at risk of dying had taken up the drug at a high price. These drugs saved the lives of a few people, but they did not make a significant difference in other areas. Because of the importance of studies and research for drugs used in the treatment of COVID-19, the market for these drugs has grown significantly. Hence boosted the market for immunosuppressant drugs globally over the forecasted period.

North America accounts for a significant share of the global immunosuppressant drugs market by geography.

The global immunosuppressant drugs market has been segmented into five major regional markets- North America, South America, Europe, the Middle East and Africa (MEA), and Asia Pacific (APAC). North America held a significant share in the global immunosuppressant drugs market in 2019. Advancements in technology and the presence of major market players in the region support the growth of this regional market. Growing demand for organ transplants and procedures boosts the demand for immunosuppressant drugs in countries like the United States and Canada, thereby driving the market growth. According to the U.S. government official data, 39,718 transplants were performed in 2019. Increasing awareness about organ donation is further paving the way for the rise in the number of transplant procedures which will boost the immunosuppressant drugs market growth during the next five years. Ninety percent of U.S. adults support organ donation. Europe also accounts for a considerable market share throughout the forecast period. The rising prevalence of autoimmune diseases in the region, coupled with R&D investments, contributes to the growth of the European immunosuppressant drugs market. In 2019, the Taxonomy, Treatments, Targets, and Remission (3TR) project was launched and funded by the E.U.'s (European Union) Innovative Medicines Initiative for the next seven years. The project aims to discover biomarkers that can predict which patients respond best to treatments for the following seven autoimmune conditions: inflammatory bowel disease, multiple sclerosis, asthma, systemic lupus erythematosus, rheumatoid arthritis, and chronic obstructive pulmonary disease. APAC and MEA will witness a substantial CAGR during the forecast period because of the rising number of organ transplant procedures supported by the booming medical tourism industry.

Market Players and Competitive Intelligence

Prominent key market players in the global immunosuppressant drugs market include Astellas Pharma Inc., Mylan N.V., Sanofi, AbbVie Inc., Veloxis Pharmaceuticals Inc., Pfizer Inc., GlaxoSmithKline plc, Dr. Reddy's Laboratories Ltd., Lupin, F. Hoffmann-La Roche Ltd, and Swiss Pharma among others. These companies hold a significant share in the market because of their good brand image and product offerings. Major players in the global immunosuppressant drugs market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last two years.

Market Launches and Strategies

April 2022

Lupin Limited (Lupin) confirmed the accomplishment of its acquisition of a brand portfolio from Anglo-French Drugs & Industries Limited (AFDIL) and its Associates. Lupin's India Formulation organisation will be strengthened by the addition of a rapidly expanding portfolio of minerals, supplements, vitamins, and neurological products. The acquisition of the AFDIL brands moves Lupin one step closer to becoming India's leading drug manufacturer.

April 2021

Pfizer Inc. announced the acquisition of Amplyx Pharmaceuticals, Inc., a privately owned company devoted to the development of treatments for devastating and life-threatening illnesses affecting people with weakened immune systems. Fosmanogepix (APX001), Amplyx's lead compound, is a novel interventional asset in the clinical development of fungal infections.

Efgartigimod

Argenx's efgartigimod appears to be on the timeline to be the first anti-FcRn drug to receive FDA approval, which is estimated could target a market worth $20 billion to $25 billion in the United States alone by 2030. The Belgian company had recently filed it with the FDA for generalised myasthenia gravis (gMG) and plans to do so with government regulators in Japan and the EU later in 2021.

Segmentation

• By Drug Class

Calcineurin Inhibitors

mTOR inhibitor

Antibodies

Others

• By Application

Organ Transplantation

Autoimmune Disorder

• By Distribution Channel

Online

Offline

• By Geography

North America

• USA
• Canada
• Mexico

South America

• Brazil
• Argentina
• Others

Europe

• Germany
• France
• United Kingdom
• Spain
• Others

Middle East and Africa

• Saudi Arabia
• UAE
• Others

Asia Pacific

• China
• Japan
• India
• South Korea
• Indonesia
• Thailand
• Taiwan
• Others